Maze Therapeutics, Inc. Common Stock MAZE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | —— | —— | —— | ||
| $115.02M+6.1% | $108.45M+5.2% | $103.09M+5.5% | $97.76M+9.6% | $89.2M+6.8% | ||
| $39.04M+13.3% | $34.45M+9.5% | $31.47M+3.0% | $30.57M+8.8% | $28.1M+6.4% | ||
| $154.05M+7.8% | $142.9M+6.2% | $134.57M+4.9% | $128.33M+9.4% | $117.3M+6.7% | ||
| -$134.05M+6.2% | -$142.9M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$122.54M+6.5% | -$131.12M— | —— | —— | —— | ||
| -$2.48+22.0% | -$3.18-116% | $19.61+95.7% | $10.02-28.5% | $14.01+1,021% | ||
| -$131.89M+6.1% | -$140.5M— | —— | —— | —— | ||
| -$134.05M+6.2% | -$142.9M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Maze Therapeutics, Inc. Common Stock's revenue?
- Maze Therapeutics, Inc. Common Stock (MAZE) generated $187.5M in revenue over the trailing twelve months.
- Is Maze Therapeutics, Inc. Common Stock profitable?
- Maze Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $122.5M over the trailing twelve months, a -65.4% net margin.
- What is Maze Therapeutics, Inc. Common Stock's earnings per share?
- Maze Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-2.48.
- Where does Maze Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Maze Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
